BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company"), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET.

Shai Novik, Executive Chairman of Enlivex, will provide an update on the Company's plans...

Related news

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-06-24 13:00 EST

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

ELTXElicio Therapeutics, Inc.2026-06-15 11:00 EST

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

CUECue Biopharma Inc2026-07-13 12:30 EST

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

INTSIntensity Therapeutics2026-07-01 12:00 EST

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

APVOAptevo Therapeutics2026-05-27 12:05 EST

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

INKTMiNK Therapeutics, Inc.2026-08-06 12:19 EST

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

IMNNImunon2026-07-23 13:25 EST

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

RNACCartesian Therapeutics2026-06-09 11:00 EST

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States